Norvium Bioscience Company Profile
✉ Email this page to a colleague
What is the competitive landscape for NORVIUM BIOSCIENCE, and what generic alternatives to NORVIUM BIOSCIENCE drugs are available?
NORVIUM BIOSCIENCE has two hundred and forty-one approved drugs.
There are four US patents protecting NORVIUM BIOSCIENCE drugs. There is one tentative approval on NORVIUM BIOSCIENCE drugs.
There are fifty-one patent family members on NORVIUM BIOSCIENCE drugs in twenty-one countries and five hundred and thirty-three supplementary protection certificates in seventeen countries.
Summary for Norvium Bioscience
| International Patents: | 51 |
| US Patents: | 4 |
| Tradenames: | 191 |
| Ingredients: | 179 |
| NDAs: | 241 |
Drugs and US Patents for Norvium Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norvium Bioscience | DEFERASIROX | deferasirox | TABLET;ORAL | 211395-001 | Mar 22, 2024 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Norvium Bioscience | DEFERASIROX | deferasirox | GRANULE;ORAL | 213146-001 | May 3, 2024 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Norvium Bioscience | FLUCONAZOLE IN DEXTROSE 5% IN PLASTIC CONTAINER | fluconazole | INJECTABLE;INJECTION | 076888-002 | Mar 25, 2005 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Norvium Bioscience | ISRADIPINE | isradipine | TABLET, EXTENDED RELEASE;ORAL | 201067-002 | Nov 27, 2015 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Norvium Bioscience | ARIPIPRAZOLE | aripiprazole | TABLET;ORAL | 206240-004 | Sep 19, 2018 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| Norvium Bioscience | CARBOPLATIN | carboplatin | INJECTABLE;INTRAVENOUS | 091063-001 | Nov 9, 2011 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Norvium Bioscience
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Norvium Bioscience | DEMADEX | torsemide | TABLET;ORAL | 020136-004 | Aug 23, 1993 | 4,822,807 | ⤷ Sign Up |
| Norvium Bioscience | ENLON-PLUS | atropine sulfate; edrophonium chloride | INJECTABLE;INJECTION | 019677-001 | Nov 6, 1991 | 4,952,586 | ⤷ Sign Up |
| Norvium Bioscience | DEMADEX | torsemide | TABLET;ORAL | 020136-003 | Aug 23, 1993 | RE30633 | ⤷ Sign Up |
| Norvium Bioscience | ZOVIRAX | acyclovir | TABLET;ORAL | 020089-002 | Apr 30, 1991 | 4,199,574 | ⤷ Sign Up |
| Norvium Bioscience | EVOCLIN | clindamycin phosphate | AEROSOL, FOAM;TOPICAL | 050801-001 | Oct 22, 2004 | 7,141,237 | ⤷ Sign Up |
| Norvium Bioscience | MIACALCIN | calcitonin salmon | SPRAY, METERED;NASAL | 020313-002 | Aug 17, 1995 | 5,759,565 | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for NORVIUM BIOSCIENCE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Foam | 0.12% | ➤ Subscribe | 2007-08-10 |
| ➤ Subscribe | Delayed-release Tablets | 20 mg | ➤ Subscribe | 2015-06-03 |
| ➤ Subscribe | Inhalation Solution | 0.021% and 0.042% | ➤ Subscribe | 2005-10-19 |
| ➤ Subscribe | Foam | 2% | ➤ Subscribe | 2009-07-30 |
| ➤ Subscribe | Topical Foam | 0.05% | ➤ Subscribe | 2005-06-27 |
| ➤ Subscribe | Ophthalmic Solution | 0.05% | ➤ Subscribe | 2006-12-13 |
| ➤ Subscribe | Nasal Spray | 0.125 mg base/spray | ➤ Subscribe | 2005-11-14 |
International Patents for Norvium Bioscience Drugs
Supplementary Protection Certificates for Norvium Bioscience Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1663240 | 300851 | Netherlands | ⤷ Sign Up | PRODUCT NAME: COMBINATIE VAN: - RILPIVIRINE OF EEN THERAPEUTISCH EQUIVALENTE VORM DAARVAN ZOALS BESCHERMD DOOR HET BASISOCTROOI, ZOALS EEN FARMACEUTISCH AANVAARDBAAR ZOUT VAN RILPIVIRINE, WAARONDER HET HYDROCHLORIDEZOUT VAN RILPIVIRINE; - EMTRICITABINE; EN - TENOFOVIRALAFENAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER TENOFOVIRALAFENAMIDEFUMARAAT; REGISTRATION NO/DATE: EU/1/16/1112 20160623 |
| 0253738 | C960002 | Netherlands | ⤷ Sign Up | PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127 |
| 1411900 | 2011/016 | Ireland | ⤷ Sign Up | PRODUCT NAME: NAPROXEN AND ESOMEPRAZOLE MODIFIED-RELEASE TABLETS; NAT REGISTRATION NO/DATE: PA0970/060/001 20101221; FIRST REGISTRATION NO/DATE: PL17901/0263-0001 20101105 |
| 0429987 | 99C0021 | Belgium | ⤷ Sign Up | PRODUCT NAME: NEVIRAPINE; NAT. REGISTRATION NO/DATE: EU/1/97/055/001 19980205; FIRST REGISTRATION NO/DATE: CH 54393 19971223 |
| 2203431 | 1590018-6 | Sweden | ⤷ Sign Up | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150119 |
| 1507558 | 2012/018 | Ireland | ⤷ Sign Up | PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
